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Abstract 
 
Within the last three decades, myxobacteria have been established as proficient 
producers of secondary metabolites that exhibit various biological activities. The 
recently finished genome sequencing project of Myxococcus xanthus DK1622 
unveilled the – at least hypothetical – potential of this myxobacterial model strain to 
be a multiproducer of secondary metabolites as well. Applying a combined genetic 
and analytical approach, indeed several natural products and the corresponding 
biosynthetic gene clusters were identified and analyzed in our institute. Among them, 
four families of metabolites – myxochelins, myxochromids, myxalamids and 
myxovirescins – were already known from other myxobacterial species. The 
DKxanthene secondary metabolite family, however, resembles a novel class of 
compounds that appears to be unique to myxobacteria, and they were shown to be 
present in all Myxococcus xanthus strains investigated to date as well as in the 
closely related species Stigmatella aurantiaca. Studies aiming at the investigation of 
the biological function of these compounds strongly suggest that they are required for 
a proper progress of the developmental program that culminates in the formation of 
fruiting bodies and mature myxospores. DKxanthenes are synthesized by a hybrid 
polyketide synthase - nonribosomal peptide synthetase machinery, and the detailed 
analysis of the biosynthetic gene cluster proposes the presence of at least one 
iteratively acting polyketide synthase module that is in large part responsible for the 
diversity of metabolites from this family. 
 VIII 
Zusammenfassung 
 
Myxobakterien wurden in den letzten drei Jahrzehnten als außergewöhnliche Quelle 
sogenannter Sekundärmetabolite mit vielseitigen biologischen Wirkungen etabliert. 
Duch die vollständige Sequenzierung des Genoms von Myxococcus xanthus wurde 
das – zumindest theoretische – Potenzial dieses myxobakteriellen Modellstammes 
als Multiproduzent von Sekundärmetaboliten aufgezeigt. Im Rahmen einer kombiniert 
genetisch-analytischen Vorgehensweise konnten im Rahmen dieser Arbeit 
tatsächlich einige Naturstoffe und die dazugehörigen Biosynthesegene identifiziert 
werden. Darunter sind vier Familien von Sekundärstoffen - die Myxocheline, 
Myxochromide, Myxalamide und die Myxovirescine - die bereits von anderen 
Myxobakterien bekannt waren. Des Weiteren konnte eine neue Familie von 
Naturstoffen - die DKxanthene - charakterisiert werden. Diese scheinen spezifisch für 
Myxobakterien zu sein, da sie in allen bisher analysierten M. xanthus Stämmen und 
auch in der nahe verwandten Spezies Stigmatella aurantiaca identifiziert werden 
konnten. DKxanthene spielen eine wichtige Funktion für den Lebenszyklus des 
Produzenten, da sie für die geregelte Fruchtkörper- und Myxosporenbildung 
notwendig sind. Die DKxanthen-Biosynthese wird durch einen kombinierten 
Polyketidsynthase-nichtribosomale Peptidsynthetase Biosyntheseapparat gesteuert. 
Die detaillierte Analyse des Biosynthese-Genclusters weist hierbei auf die 
Mehrfachnutzung von mindestens einem Polyketidsynthase-Modul hin; eines von 
mehreren Besonderheiten, die zu der chemischen Diversität dieser Naturstoffe führt.   
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1. Myxobacteria 
 
Myxobacteria are obligate aerobic, chemotrophic Gram-negative δ proteobacteria 
that most commonly inhabit the soil. The recent discovery of novel myxobacterial 
species from marine as well as moderate halophilic environments (53,54) proves the 
ability of myxobacteria to adapt towards differing environmental conditions. The 
vegetative cells of myxobacteria are typically rod-shaped, 3-12 µm in length and 0.7-
1.2 µm in width (110). When grown in nutrient-rich liquid media, myxobacteria usually 
grow as independent cells. However, on solid surfaces such as an agar plate, they 
interact with each other and swarm on the agar surface in order to gain access to 
nutrients that are not in immediate proximity to the bacteria. Many myxobacterial 
species secrete lytic enzymes which allow them to prey on other bacteria and yeasts 
(65,107) and to digest the released proteins, lipids and nucleic acids. In absence of 
any nutrient, myxobacteria stop the swarming behaviour and instead start to build up 
aggregates, a process that finally culminates in the formation of fruiting bodies. This 
complex life cycle that includes the formation of myxospores within the mature 
fruiting body is one of the outstanding features of myxobacteria.  
Myxobacteria constitute the order Myxococcales, which can be further differentiated 
into the suborders Cystobacterineae, Nannocystineae and Sorangiineae (109). 
Sorangium cellulosum from the latter suborder exhibits the unique capability among 
myxobacteria to degrade cellulose and to use it even as the sole carbon-source, a 
property that supports the isolation of Sorangium species from environmental 
samples (110).  
Eight genera are known from the suborder Cystobacterineae, which is furthermore 
split into two families: The Myxococcaceae  constituting of the genera Myxococcus, 
Corallococcus and Pyxidicoccus while Archangium, Cystobacter, Hyalangium, 
Mellitangium and Stigmatella belong to the Cystobacteraceae (109). 
Among them, the genus Myxococcus and especially the species Myxococcus 
xanthus represents the best studied organism among the myxobacteria since its life-
cycle can be investigated very reproducible under laboratory conditions.  
Another remarkable feature of myxobacteria - which might at least in part be caused 
by the complex life cycle when compared to other bacteria - is the overall large size 
of myxobacterial genomes. The recently sequenced genome of Sorangium 
cellulosum So ce56 resembles the so far largest known bacterial genome with a size 
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of 13.0338 Mb (118). The genome size of Stigmatella aurantiaca was estimated as 
9.5 Mb (123), and  the Myxococcus xanthus DK1622 genome was shown to be 9.14 
Mb in size (44,66). The extraordinary large size as well as the high number of genes 
in the Myxococcus genome in comparison to all other so far sequenced non-
myxobacterial δ proteobacteria was supposed to be at least in part based on 
extensive gene duplications. These gene duplications do not evolve by coincidence 
but rather include genes which are important for the myxobacterial life cycle, such as 
genes encoding proteins necessary for intercellular  signalling (44). 
 
1.1 Cooperative behaviour and life cycle of Myxococcus xanthus 
 
Myxobacteria are assumed to be one of the earliest models in nature that explored 
the possible advantages of progressing from a single cell state to a social 
multicellular life style (30,122). However, myxobacteria retained their capability to 
grow as single cells rather than to further differentiate into obligate multicellular 
organisms. Multicellular behaviour requires several prerequisites like the ability to 
distinguish between sibling cells and cells from foreign species, spatial 
morphogenesis as well as the capability to exchange information from cell to cell, a 
process which is described as intercellular signalling (66,124). Several classes of 
mutants unable to form fruiting bodies or spores were identified and shown to arrest 
at specific time points during development, inferring the blocking of important signals. 
These mutants were grouped according to the pattern of synergism that lead to 
complementation of the developmental defect of one group when mixed with another 
group (47). Currently, five groups (A-E) of rescuable mutants are recognized, which 
have defects in the asg, bsg, csg, dsg or esg genes, respectively (27,47).  
Multicellular social behaviour is induced when cells are starved on solid surfaces and 
when the bacteria “sense” that the overall cell number is high enough to enter the 
developmental process which will favour the survival of the population.  
M. xanthus moves by gliding in the direction of its long axis by using two motility 
systems. Social (S-) motility is dependent on the presence of type IV pili that attach 
to nearby cells and subsequently are retracted, thus pulling the cells together (63,64). 
Adventurous (A-) motility enables the cells to glide as individuals. The mechanism 
underlying A-motility is unclear until now- the extrusion of slime from the cell poles 
through nozzle-like structures as the force for the propulsion was proposed (158), 
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and recently, a novel model describing focal adhesion complexes was introduced. 
Here, the attachment of intracellular motor complexes to membrane-spanning 
adhesion complexes and to the cytoskeleton were supposed to power motility by 
pushing against the substratum and thus moving the cell forward (93).  
Starvation induces a shift from (adventurous) swarming behaviour towards the 
migration to aggregation centers which can be seen after about 4-6 hours. Within the 
first 24 hours of development, these loose aggregates become hemispherical 
mounds that each contain up to 1.000.000 cells. Approximately 10-20 % of the cells 
within the mounds differentiate into non-motile, heat- and sonication-resistant 
myxospores. The remaining cells undergo autolysis, most presumably in order to 
provide the essential nutrients for the surviving cells to undergo the differentiation 
into myxospores (157). Cells left outside the fruiting body remain rod shaped, but 
have a different protein expression pattern when compared with vegetative cells and 
myxospores. The role of these “peripheral rods” was proposed to be a backup of 
cells that take advantage of low nutrient levels that would not support germination 
and outgrowth of the developmental spores (102-104). Alternatively, peripheral rods 
might play a role in defending the dormant fruiting body from consumption and 
colonization by other microbes (124) (Figure 1 pictures the time series of fruiting 
body formation of a M. xanthus submerged culture).  
Besides the described differentiation into specialized cell types during fruiting body 
formation, M. xanthus cells growing under vegetative conditions undergo a phase 
variation between two alternate phases which are depicted by their pigmentation 
phenotype - the predominant colony type exhibiting the characteristic yellow colour 
that is the name giver of the species M. xanthus (yellow phenotype), meanwhile cells 
from the other phase are almost unpigmented and accordingly, this state is named 
the tan phenotype (18,19). Pure populations of mutants locked into the tan phase 
were shown to be unable to form fruiting bodies. Despite starting the differentiation 
process, cells did not form true spores after developmental induction, but rather 
developed phase-dark, round forms that were unable to complete the maturation to 
heat- and sonication-resistant, refractile  spores (81,82). This defect in development 
could be restored by the addition of phase-variation proficient cells from predominant 
yellow cultures. In such mixtures, the tan-phase locked mutants were preferentially 
represented among the viable spores, and specific roles for each cell type were 
proposed: The tan cells within a population were suggested to be the progenitors of 
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spores, whereas the yellow cells might direct fruiting body formation and spore 
maturation through intercellular signalling (82,124). Similar observations were made 
in further experiments: Extracellular complementation of sporulation deficient group C 
mutants with group B strains showed only slight, if any, synergy in developmental 
complementation when yellow group C populations were used. Inclusion of a few 
percent of tan group C cells strongly stimulated the developmental synergism (62). 
Experiments investigating the glucosamin-induced cell lysis and subsequent 
sporulation of M. xanthus cells revealed that tan cells are more resistant to 
glucosamin-induced lysis, but yet were required for glucosamin-induced sporulation 
(97). Even though these observations strongly suggest an involvement of phase 
variation in the developmental life cycle of M. xanthus, still little is known about the 
mechanism of phase variation.  
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Figure 1. Fruiting body formation of Myxococcus xanthus in submerged culture 
(adopted from Kuner and Kaiser, 1982 (76)) 
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 2. Natural products 
 
2.1 Natural products and their relevance in clinical therapy  
 
Secondary metabolites from plants, fungi as well as bacteria constitute a daily 
growing library of compounds of natural origin that not only exhibit a vast diversity of 
chemical structures. More importantly, natural products and compounds which were 
developed from natural product lead structures, proved to be useful in the treatment 
of various diseases and in agrochemical applications such as crop-fungicides. 
Besides the use of complex therapeutic mixtures (such as extracts of herbs with 
boiled water) which was applied already thousands of years ago and which is still in 
use even in occidental medicine, the discovery and purification of single compounds 
with biological activities resembles a milestone of modern medical treatment. Among 
these, the discovery of penicillin - which is still in clinical use for the treatment of 
bacterial infections - by Alexander Fleming in 1928 from the fungus Penicillium 
notatum (83) and the discovery of morphine as the pain-relieving principle of the 
poppy Papaver somniferum L. more than two hundred years ago by Friedrich 
Sertürner (101) picture early hallmarks of this new era of natural product research. 
Since then, natural products have been established as useful sources for novel, non-
synthetic drugs and drug-leads. Seventythree percent of the drugs used in clinical 
treatment of cancer are not derived from synthetic chemistry; 47% represent the 
natural products themselves or are directly derived thereof (100). Examples for 
potent antitumor drugs from natural producers are paclitaxel and doxorubicin. Further 
important fields of therapeutics besides cytostatic agents include various antibiotics- 
such as the already mentioned β-lactam antibiotics, but also erythromycin, 
tetracycline, streptomycin or vancomycin-, in addition immunosuppressive drugs like 
cyclosporine and rapamycin as well as the cholesterol-lowering agent lovastatin 
(selected structures are shown in Figure 2). 
Besides the broad application of natural products in medicine, Figure 2 exemplifies a 
further characteristic feature of secondary metabolites: the unique structural diversity 
found in nature. The recruitment of various different building blocks as well as the 
activity of diverse modifying enzymes leads to the construction of very often highly 
complex chemical structures exhibiting various stereocenters. On average, natural 
products differ from most synthetic structures by the incorporation of a higher number 
Introduction 
 
8 
of oxygen atoms and a higher steric complexity, whereas synthetic drugs usually 
comprise more nitrogen-, sulphur- and halogen-containing groups. Natural products 
can be regarded as privileged structures since they were selected for by evolutionary 
pressure, thus enabling the specific interaction with diverse biological targets (72).  
 
 
Figure 2. Selected chemical structures of natural products with diverse modes 
of action  
 
In order to produce these diverse structures, microorganisms often employ large 
multifunctional enzyme complexes. Three frequently used systems are polyketide 
synthases (PKSs), nonribosomal peptide synthetases (NRPSs) as well as hydrid-
systems thereof which use activated carboxylic acids or amino acids, respectively, as 
simple building blocks that are incorporated into the growing precursor molecule 
(34,134,145,146). The genes encoding the biosynthetic enzymes are frequently 
found to be clustered on a small segment of the respective bacterial chromosome. 
PKS systems can be further classified based on the chemical structure of the 
released product and on their mode of biosynthesis. For instance, fungal type I PKSs 
are characterized by the repetitive use of a single modular enzymatic system (a 
process described as iterative usage) (35,87). In contrast, the bacterial modular type 
I PKS is the most propagated one among bacteria. Here, the genes encoding the 
modular organized assembly lines are mostly clustered within the microbial genome, 
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and biosynthesis usually follows a colinear principle in which the backbone structure 
of the natural product can be correlated with the organization of the biosynthetic 
modules and catalytic domains (134). Typical products of modular type I PKSs are 
polyenes or macrolides such as erythromycin (149).  
Bacterial type II PKSs consist of one set of discrete polypeptides that form a catalytic 
complex and which are used iteratively, usually leading to phenolic aromatic 
compounds such as actinorhodin (33,49). Finally, type III PKS systems belonging to 
the chalcon synthase and stilben synthase family are typical for the secondary 
metabolism of plants, but were recently also discovered in bacteria and fungi 
(5,7,45,121). Yet, more and more examples of PKSs that drop out of the borders of 
classified PKS systems emerge, and a new classification or the surrender of any 
classification system seems to be necessary (96,98).  
The following description will focus on bacterial type I PKS systems and on 
nonribosomal peptide synthetases (NRPSs), since these are the most abundant in 
myxobacterial biosynthetic machineries and the relevant ones for this work. NRPSs 
have a similar structure as type I PKS systems (which will be called PKS in the 
following section for simplification).  
 
2.2 Polyketide and nonribosomal peptide biochemistry 
 
In both, polyketide and nonribosomal peptide biosynthesis, the growing chemical 
scaffold is build up by a series of condensing elongation steps with short carboxylic 
acid units or proteinogenic as well as nonproteinogenic amino acids, respectively. 
PKSs and NRPSs have a modular structure and follow the so-called “multiple carrier 
thio-template mechanism” (120,135). According to this model, repetitive catalytic 
units termed modules are responsible for the incorporation of one residue into the 
growing polyketide or nonribosomal peptide chain. During the assembly, the 
intermediates of the growing natural product remain tethered to the carrier protein of 
the respective module through a thioester-linkage. The carrier proteins themselves 
have to be activated through the activity of a phosphopantetheinyl transferase (Ppant 
transferase) that transfers a 4’-phosphopantetheine cofactor onto a conserved serine 
residue of the apo-carrier protein (Figure 3). The Ppant moiety serves two main 
functions during the natural product assembly: To activate the growing intermediate 
in a covalent and energy-rich linkage with the enzyme and furthermore to serve as a 
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flexible arm that facilitates the transport of the intermediates to the distinct catalytic 
centers - which are called domains - of the multifunctional enzyme (80,95,148).  
 
Figure 3. Activation of the apo-carrier protein (ACP or PCP) through the activity 
of a phosphopantetheinyl-transferase (PPTase)  
 
Before attachment to the carrier protein (CP), the monomeric elongation unit has to 
be selected for by either acyltransferase (AT) or adenylation (A) domains in PKSs 
and NRPSs, respectively. After transfer to the carrier protein, a third catalytic domain 
accomplishes the chain extension resembling a thio-claisen condensation for PKSs 
and an amide bond formation in the case of NRPSs. The completely processed acyl-
chain is finally released from its covalent thioester linkage through the activity of a 
termination domain such as a thioesterase (TE) or a reductive (R) domain. 
Figure 4 shows the general processing of intermediates in PKS biochemistry. In the 
first step (Figure 4, Step 1) the acyl transferase (AT) domain selects for the 
respective CoA-activated starter or extender unit and transfers it onto the acyl carrier 
protein (ACP) of the corresponding biosynthetic module. Whereas the extender units 
are usually derived from malonyl-CoA and methylmalonyl-CoA, the starter units have 
been shown to be recruited from diverse sources of CoA-esters of short chain 
aliphatic as well as aromatic carboxylic acids. Subsequently, the ACP-bound 
intermediate of the upstream module (which is the loading module in the case of 
Figure 4) is transferred to a conserved cystein residue of the β-ketoacyl synthase 
(KS) domain of the downstream module and nucleophilically attacked by the α-
carbon of the ACP-bound elongation unit (Figure 4, Step 2). After decarboxylative 
condensation of starter and elongation unit, the biosynthetic intermediate that now is 
extended by one additional C2 unit remains attached to the ACP of the elongation 
module (Figure 4, Step 3). From here, the growing chain can be passed on to the 
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KS domain of the downstream module and thereby undergo another condensation 
reaction. Alternatively, in the presence of several additional catalytic domains, the 
intermediate might be channelled through several reductive steps before being 
passed on to the next module. A complete “reductive loop” (134) consists of a β-
ketoacyl reductase (KR), a dehydratase (DH) and an enoyl reductase (ER) domain. 
The catalytic order of these domains is different from their order on the protein. KR 
domains catalyze the stereospecific reduction of a β-keto-function to the alcohol 
which can be further dehydrated and subsequently reduced to the α,β-methylene 
derivative through the activity of a DH and an ER domain, respectively (Figure 4, 
Steps 4-6).  
 
 
Figure 4. Schematic overview of polyketide synthase (PKS) biochemistry. The 
short chain carboxylic acid starter and extender units are selected for by acyl 
transferase (AT) domains and loaded onto the respective acyl carrier protein 
(ACP) (1). The thioester-linked intermediates subsequently undergo a 
decarboxylative condensation catalyzed by a β-ketoacyl synthase (KS) domain 
(2 and 3). Further optional domains might introduce additional structural 
modifications (4-6). Domains involved in catalysis of the respective reaction 
step are indicated by grey shading.  
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NRPS biochemistry follows a very similar procedure when compared to polyketide 
biosynthesis, as shown in Figure 5. Here, an adenylation (A) domain first selects for 
and furthermore activates the respective amino acid in an ATP-dependent reaction 
giving rise to its aminoacyl-adenylate derivative, which is subsequently transferred to 
the peptidyl carrier protein (PCP) (Figure 5, Steps 1 and 2). The condensing 
reaction - which in the NRPS case leads to an amide-bond formation - is catalyzed 
by the condensation (C) domain of the elongation (downstream) module (Figure 5, 
Step 3). Again, several modifying enzymes accomplish a higher diversity in natural 
product biosynthesis, a few examples are epimerization, (N)-methylation as well as 
heterocyclization (Figure 5, Steps 4-6). The latter is performed by specialized C 
domains (HC = heterocyclization domains) that catalyze the peptide bond formation 
and the subsequent cyclization and dehydration reaction, usually using cysteine, 
serine or threonine as the substrates. The resulting oxazoline (derived from serine 
and threonine) or thiazoline (derived from cysteine) ring system might be further 
oxidized to an oxazole or thiazole moiety (Figure 5, Step 7). 
After the last elongation step, the enzyme-bound nonribosomal peptide, polyketide or 
NRPS/PKS-hydrid intermediate is released from its biosynthetic template, usually 
through hydrolytic cleavage catalyzed by a thioesterase (TE) domain that releases 
the free acid or, by intramolecular cyclization, a macrolacton- or macrolactam-
structure.  
Very common in nature are further chemical modifications that occur after the release 
of the natural product from the thio-template, such as glycosylations or additional 
oxygenation steps, many of which have proven to be essential for the bioactivity of 
the natural product (100).  
A very high degree of conservation has been found for the delineated types of 
enzymes and domains, and several critical sequence motifs were identified that are 
necessary for the recognition (159) and activation (22,73,144) of the substrate, the 
attachment of the intermediate (156) as well as the catalytic activities such as 
condensing (73,156) and reductive reactions (112,156). 
With the growing knowledge about polyketide and nonribosomal peptide 
biosynthesis, based on sequence as well as functional analysis of newly 
characterized biosynthetic gene clusters, the way is paved for the emerging field of 
combinatorial biosynthesis (21,28,90). The theoretically unlimited combination of 
PKS and NRPS systems and modifying enzymes opens up the opportunity for the 
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generation of even larger chemical libraries as well as structure-activity guided 
approaches in order to improve e.g. the selectivity of a natural product derived drug. 
 
 
Figure 5. Schematic overview of nonribosomal peptide synthetase (NRPS) 
biochemistry. Amino acid starter and elongation units were selected and 
activated by adenylation (A) domains, attached to the peptidyl carrier protein 
(PCP) (1 and 2) and finally condensed by condensation (C) domains (3). Again, 
several optional domains (4-7) might lead to modifications in the chemical 
scaffold. Epimerization domains (4) generate an equilibrium of L- and the 
respective D-amino acids, and the C domain of the downstream module selects 
for one specific enantiomer. Domains involved in catalysis of the respective 
reaction step are indicated by grey shading (X = O, S).  
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3. Myxobacteria as multi-producers of secondary metabolites 
 
Besides the readily established microbial secondary metabolite producers 
actinomycetes and fungi, the research on myxobacteria as novel sources for natural 
products only gained its legitimate attention within the last three decades. In a 
screening program performed at the former GBF (Gesellschaft für Biotechnologische 
Forschung, now Helmholtz Zentrum für Infektionsforschung, HZI), more than 100 
new chemical core structures and additionally approximately 500 derivatives were 
isolated from altogether more than 7,500 different myxobacterial strains (for selected 
examples, see Figure 6) (13,43,108). Moreover, many of these natural products 
could be assigned diverse biological activities with unusual, rarely found mode of 
actions. Myxovirescin (141) and sorangicin (20,56) are examples for potent 
antibiotics from myxobacterial origin. In particular the latter, sorangicin, which targets 
the bacterial RNA polymerase beta subunit in a similar manner as the clinically used 
tuberculosis-antibiotic rifampicin has the potential to be a new drug-lead since 
sorangicin proved to be not as sensitive to mutations in the enzyme`s binding pocket 
which is shared between the two compounds (20). Myxothiazol (41,138,140), 
melithiazol (15,115), stigmatellin (78,137) and soraphen (8,16,39) are bioactive 
against several fungi, with soraphen being a potent inhibitor of the novel antifungal 
target-enzyme acetyl-CoA-carboxylase (8,16,39,106,111). Of special interest are 
compounds that interact with the eukaryotic cytoskeleton. Among these, the 
microtubuli-stabilizer epothilone (2,51,52) has served as a very promising drug-lead, 
with several natural and non-natural derivatives being investigated. Ixabepilone has 
recently finished the phase III clinical trials and was approved for the treatment of 
breast cancer by the FDA (24). Epothilone binds to tubulin and thus stabilizes the 
microtubuli in a similar fashion as the established anticancer-drug paclitaxel, but at 
least in part through a nonoverlapping mode of action (2,24). Avoidance of cross-
resistances might be also achieved by targeting the cytoskeleton through a different 
mode of action exhibited by other bioactive secondary metabolites. This holds true 
for tubulysin (68,70,116) and disorazol (32,57,59), since these compounds do not 
stabilize but rather destabilize the microtubuli.  
Furthermore, myxobacteria as well as other bacteria produce compounds that act as 
iron-chelators, so called siderophores, in order to sequester the essential metal from 
their environment (3). Myxochelin (77) was identified as the most often used iron-
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chelating principle in myxobacteria. Additionally, it shows weak antibacterial activity 
against Gram positive bacteria and recently an inhibitory effect on the invasion of 
murine colon 26-L5 carcinoma cells was described in vitro (94).  
 
Figure 6. Selected myxobacterial natural products. Information about the 
respective biological activity or function is given in section 3 
 
 
4. Outline of the present work 
 
4.1 The potential of Myxococcus xanthus DK1622 as a multi-producer of 
secondary metabolites 
 
Despite detailed investigations as the model strain for myxobacterial development, 
nothing was known about secondary metabolism in M. xanthus DK1622 until recently 
(13). The Myxococcus xanthus genome sequencing project (44) and the subsequent 
in silico-analysis revealed the presence of at least 18 biosynthetic gene clusters from 
the NRPS- or hybrid PKS/NRPS-type (Figure 7, red bars in layer 4), indicating the – 
at least hypothetical - potential of this strain to be a multi-producer of natural 
products. Remarkably, a large part of these 18 identified biosynthetic gene clusters 
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were shown to be located in close proximity to each other on the chromosome, with 
most of the biosynthetic genes being clustered between 1.5 and 3.5 Mb as well as 
between 4.4 and 5.8 Mb on the 9.14 Mb chromosome (44).  
 
 
Figure 7. Genome map of Myxococcus xanthus DK1622. The red bars in layer 4 
indicate the position of genes dedicated to secondary metabolism. Layer 1: 
Genes expressed in clockwise direction, layer 2: genes expressed in 
counterclockwise direction, layer 3: lineage-specific duplications, layer 5: GC 
nucleotide skew (adopted from Goldman et al. 2006 (44))  
 
Altogether 8.6 % of the M. xanthus genome is dedicated to secondary metabolism, a 
percentage higher than in various other established secondary metabolite producers 
(9,105). Comparison of the newly identified biosynthetic gene clusters in M. xanthus 
DK1622 with gene clusters that were already known from other myxobacteria led to 
the identification of the biosynthetic gene clusters of myxalamid (cp. Stigmatella 
aurantiaca Sg a15), myxovirescin (cp. Myxococcus virescens), myxochromide (cp. 
Stigmatella aurantiaca DW4/3-1) and myxochelin (cp. Stimatella aurantiaca Sg a15) 
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(42,60,77,126-128,139,141,152,153) in M. xanthus (for chemical structures, see 
Figure 8). The mentioned metabolites - including in part novel derivatives - could be 
identified in M. xanthus DK1622 in the scope of this work. Structure elucidation was 
performed after applying large-scale fermentation and the subsequent isolation and 
one- and two-dimensional NMR analysis as well as HPLC-MS and MS/MS analyses 
in combination with  feeding experiments (11,128,153) (myxochelin unpublished). 
Each family of metabolites will be described in more detail in the discussion section. 
 
 
Figure 8. Natural products identified in Myxococcus xanthus extracts that were 
already described from other myxobacterial secondary metabolite producers  
 
The structures and biological functions of further (novel) secondary metabolites from 
M. xanthus DK1622 were unknown at the starting point of this study. The isolation 
and structural characterization of natural products from M. xanthus DK1622 and, 
where possible, the determination of their physiological roles were hence a key issue 
of the presented thesis. The identification and optimization of production conditions 
for the respective metabolite represent a decisive point for a successful performance 
(10). Many biosynthetic gene clusters might be “switched off” under laboratory 
conditions (so called silent gene clusters), and it was one goal of this study to induce 
the production of these putatively novel compounds. In order to do so, several 
differing cultivation conditions, including the variation of media, temperature and 
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extraction procedures as well as induction of fruiting body formation and sporulation 
were applied, and the secondary metabolite profile was determinded by HPLC-MS. 
Furthermore, the biosynthetic gene cluster responsible for the production of the 
pigments that give M. xanthus its characteristic yellow appearance was identified 
through transposon mutagenesis in the beginning of this work (performed by Dr. 
Helge B. Bode). Besides the purification and chemical characterization of the yellow 
pigments, the analysis of the biosynthetic machinery that drives their production as 
well as investigations into the biological function of these metabolites was a major 
goal of this work. 
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Chapter 4 
 
Identification and structure-elucidation of 3’’-O-methylmyxochelin A 
(unpublished) 
Chapter 4 
29 
Summary 
A novel, methylated derivative of myxochelin A was discovered in the course of an 
attempt to investigate the chemical principle underlying a strong cytotoxic activity 
found in Myxococcus xanthus extracts. For fractionation, an activity-guided approach 
was chosen. M. xanthus DK1050 was cultured in rich medium, extracted and 
fractionated applying several subsequent chromatographic separation steps, and 
fractions were tested for bioactivity. Since the main activity was finally observed in a 
fraction containing solely the known myxochelins A and B as well as an unknown 
compound, the separation-strategy was changed in order to purify the novel 
compound. Purification of a methylated myxochelin A and the testing for cytotoxicity 
in comparison to the known myxochelins did not unveil any difference in activity 
among the derivatives. Rather, the discovery of a methylated myxochelin A derivative 
suggests a novel mechanism of iron release.  
 
Introduction 
Siderophores are small molecules synthesized by bacteria, fungi and even some 
plants that exhibit a very high affinity towards Fe(III). In bacteria, they are usually 
build up from nonribosomal peptide synthetases and after their biosynthesis, they are 
secreted into the bacterial environment in order to sequester the essential trace 
element. From the exterior, the Fe(III)-siderophore complex is specifically recognized 
by outer membrane receptors and internalized, in Gram-negative bacteria usually 
mediated by the TonB-ExbB-ExbD protein complex (6). The intracellular iron release 
is a process less well understood. For enterobactin, a hydrolytic mechanism is 
described. In other systems, enzymes with ferric reductase activity are thought to be 
involved in iron release, since Fe(II)-siderophore complexes exhibit weaker affinities 
than the respective Fe(III) complexes (5). However, so far there is no experimental 
evidence for these hypotheses. In an activity-guided approach aiming at the isolation 
of a cytotoxic compound from M. xanthus, an O-methylated myxochelin derivative 
was isolated here. The discovery of the modified siderophore might provide useful 
information about the mechanism of iron release in myxobacteria. 
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Results: 
Isolation and structure elucidation of 3’’-O-methylmyxochelin A. Two liters of a 
M. xanthus culture was grown in CTT medium in presence of 1% of the adsorber 
resin Amberlite XAD-16, harvested and extracted with ethylacetate/methanol (1:4) 
and fractionated by gel permeation and isocratic RP-high performance liquid 
chromatography. The obtained fractions were tested for cytotoxicity applying the MTT 
test (12) on L929 mouse cell lines, and chemically analyzed using thin layer 
chromatography and HPLC-MS (-MS/MS). As the activity narrowed down to a 
fraction containing the known myxochelins A and B ((M+H]+ m/z 404 and m/z 405) 
(2,9) and apparently only one further compound (m/z 419), the strategy was changed 
from the activity-guided to a classical analytical approach in order to purify the 
unknown compound by sequential RP-HPLC chromatography. The final yield of the 
purified compound was 2 mg. By 13C NMR analysis (Table 1) the total number of 
carbons could be determined as 21, with 12 signals found between 114 and 150 ppm 
indicating the presence of several double bonds and two signals assignable to ester 
or amide bonds (δC169 and 170, respectively). Through 1H NMR analysis six protons 
(δH 6.67-7.31) could be determined as part of an aromatic moiety, and heteronuclear 
single quantum correlation (HSQC) spectroscopy allowed their assignment to six 
carbons between 116 and 120 ppm. HSQC and heteronuclear multiple bond 
correlation (HMBC) as well as 1H-1H-correlated spectroscopy (1H-1H-COSY) 
experiments elucidating the chemical neighbourhood of these protons led to the 
identification of two separated dihydroxy-benzoyl moieties (COSY- and HMBC-
correlations are shown in Figure 1). A singlet at 3.85 ppm indicated the presence of a 
methoxy-moiety. Weak 1H-1H-COSY correlation of the methyl protons of this 
methoxy-moiety to H-4’’ as well as HMBC correlation to C-3’’ indicates that OH-3’’ of 
the respective dihydroxy-benzoyl moiety is methylated in the isolated metabolite. 
Each dihydroxy-benzoyl unit is attached to one amino-group (α- or ε-, respectively) of 
a reduced lysine as could be assigned through HMBC correlation of H-2 and H-6 of 
the lysinol moiety to C-7’ and C-7’’, respectively. The structure of the lysinol could be 
elucidated through 1H-1H-COSY, HSQC and HMBC experiments, leading to the final 
structure determination of 3’’-O-methyl-myxochelin A (Figure 1 and Table 1). 
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Figure 1. Numbering of myxochelins (A: R = OH, B: R = NH2; left structure), and selected 1H-
1H-COSY (bold lines) and HMBC (arrows) correlations of 3’’-O-methylmyxochelin A (right 
structure) 
 
 
Table 1. 13C and 1H spectral data of 3’’-O-methylmyxochelin A in [D6]DMSO at 500 MHz 
(1H) and 125.7 MHz (13C) 
Number 13C 1H J, Hz 
1 64.8 3.61 dd 5.2/7.9 
2 52.5 4.14 m  
3 31.4 1.63 m  
4 31.2 1.75 m  
5 29.9 1.68 m  
6 40.0 3.39 m  
1’ 115.6   
2’ 148.6   
3’ 148.8   
4’ 119.0 6.90 d 7.6 
5’ 119.2 6.67 t 7.9 
6’ 118.0 7.26 d 7.0 
7’ 170.0   
1’’ 114.5   
2’’ 149.1   
3’’ 148.4   
4’’ 116.0 7.05 d 8.2 
5’’ 119.4 6.80 t 8.0 
6’’ 120.5 7.31 d 8.2 
7’’ 169.0   
3’’-OMe 56.7 3.85 s  
s, singlet; d, doublet; m, multiplet; t, triplet; dd, doublet of doublet 
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Discussion: 
Myxochelins are iron-chelating siderophores known from several myxobacteria (9,14) 
as well as non-myxobacterial species (11). As observed for many other siderophores, 
the iron-uptake is facilitated by the chelation of Fe(III) with –in this case two- 2,3-
dihydroxy-benzoyl (catecholate) subunits. Enterobactin resembles a further 
siderophore from this class and its “iron-metabolism” including the mechanism of 
iron-release was investigated in detail (3). It is produced by several Gram-negative 
enteric bacteria and exhibits three such catecholate subunits which are connected 
with each other by a triserine-lactone backbone. Iron taken up from the environment 
as the Fe-enterobactin catecholate complex is primarily released intracellular by the 
esterase Fes (10). Yet, an alternative mechanism for iron release from enterobactin 
was proposed since synthetic analogues of enterobactin that were not susceptible to 
hydrolysis retained the ability to supply the cells with iron sufficiently. Here, iron 
release through reduction of Fe(III) from its salicylate complex enabled by 
protonation of the meta-hydroxy function of the catecholate structure was proposed 
(1).  
At the onset of this work, nothing was known about the mechanism of iron-release 
from the myxochelins. A cleavage of one or both amide bonds would - in conformity 
with the iron-release from enterobactin - destroy the siderophore and would at least 
in part enable the reuse of the myxochelin building blocks. Besides this theoretical 
mechanism, the hereby reported discovery of an O-methylated myxochelin A 
derivative hints at an alternative mechanism. Driven by methylation, the Fe(III)-
myxochelin complex is very likely shifted from the catecholate to the salicylate form, 
from which reduction of Fe(III) to Fe(II) and the subsequent iron release is 
significantly favoured. Through feeding experiments with L-methionine-methyl-d3, it 
was demonstrated that the methylation is catalyzed within the cells (7). Furthermore, 
the presence of a methylated myxochelin B derivative is strongly proposed since a 
metabolite with the expected mass, fragmentation pattern as well as the expected 
mass shift in the described feeding experiment was observed. Yet, structure 
elucidation of this metabolite failed so far, mainly due to productivity reasons (7). 
Since inactivation of seven preselected (O-)methyltransferase/SAM-dependent 
protein encoding genes from M. xanthus did not lead to a loss of the methylated 
derivative (7), the most promising methyltransferase (MXAN_5681; chosen according 
to its location in close proximity of genes encoding proteins with hypothetical 
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functions in iron metabolism) was chosen for heterologous expression in E. coli in 
order to pave the way for subsequent in vitro experiments (T. Klefisch, unpublished). 
Here, purified or chemically synthesized myxochelin will serve as the substrate that is 
supposed to be methylated in meta-position by the active methyltransferase. Apart 
from this necessary proof of principle, information about the regioselectivity of the 
methyltransferase can be gained from these experiments since at least in theory 
three additional phenolic groups might be methylated besides the observed 3’’-OH 
function. In parallel to the expression experiment, myxochelin A as well as its 
methylated derivative is going to be synthesized in order to determine the 
coordination chemistry and reduction potential of both metabolites with respect to 
Fe(III) (in collaboration with M. Bartholomä, K. Hegetschweiler, Arbeitskreis für 
Komplexchemie, Saarland University). It is expected that the methylated myxochelin 
derivative forms a salicylate rather than the catecholate complex (as postulated for 
the unmethylated myxochelins) with ferric iron, and consequently, that the reductive 
release is highly favoured from the methylated form.  
Taken all of these considerations together, an unprecedented mechanism of iron 
release is proposed based on the methylation-dependent distortion of the 
siderophore-iron complex: Ferric iron (Fe(III)) is sequestered from the environment 
by the siderophore myxochelin and taken up into the cell, and the iron-siderophore 
complex prevents the cell from direct toxic effects of Fe(III). The iron release from this 
complex might be triggered through methylation of the siderophore. As the most 
likely candidate protein for methylation, the methyltransferase MXAN_5681 is 
currently under investigation. This methyltransferase is part of an operon together 
with several other genes presumably involved in iron homeostasis. The operon is 
presumably under the transcriptional control of FUR (ferric uptake regulator protein), 
since a typical DNA-FUR binding box is located upstream of the first gene of the 
operon. FUR usually binds ferrous iron and subsequently binds to promoter regions 
as a homodimer, acting as a positive repressor. Without this repression – at low 
ferrous iron level - MXAN_5681 (or an alternative methyltransferase) might be 
expressed, leading to the (meta-OH)-methylation of the myxochelin-Fe(III) complex, 
the described shift in coordination, the reduction of Fe(III) to Fe(II) and thus 
eventually to the release of iron. This refined system for a crucial process of the 
bacterial cell would be another example among many decribing how M. xanthus is 
capable to perform a very complex and adjustable life cycle.  
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Materials and methods: 
Isolation of the compound. M. xanthus DK1050 (13), a stable yellow derivative of 
strain M. xanthus FB (4) was cultivated at 30°C in two liters of CTT medium (8) in 
presence of 1% Amberlite XAD-16. Cells and XAD were harvested after three days of 
growth and extracted repeatedly with overall 500 ml of ethylacetate/methanol (1:4). 
Subsequently, the crude extract was first separated by gel permeation 
chromatography (Sephadex LH20 in methanol) into six fractions. Fractions exhibiting 
strong activity in the MTT-test were pooled and further separated applying several 
sequential isocratic RP-HPLC purification steps, yielding 2 mg of purified 3’’-O-
methylmyxochelin A (Jasco HPLC (PU-2087, UV-2075), Nucleosil 250/21 RP18, 
Macherey-Nagel, MeOH/H2O 70:30, detection at 254 nm). 
 
Structure elucidation. The structure of 3’’-O-methylmyxochelin A was elucidated 
using 1D (1H, 13C) and 2D NMR (1H,1H-Cosy, HSQC, HMBC) analysis on Bruker 
DRX 500 or Bruker Avance 500 spectrometers using [D6]DMSO. HPLC-MS and -
MS/MS-experiments were performed using an acetonitrile:water gradient (5-95 % 
acetonitrile with 0.1% formic acid, HPLC: Agilent 1100 series, MS: Bruker HCT Plus 
ion trap). 
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Statement about the author’s effort in Chapters 
1-6 
 
Chapter 1: The author performed in part the chemical analysis of the described 
feeding experiments. Isolation of [2-13C]-acetate enriched myxalamid B from several 
M. xanthus and S. aurantiaca strains as well as isolation of the two novel 
mutasynthesis derived myxalamid derivatives was performed by the author or in 
close collaboration with the author. The author participated in the subsequent 
structure elucidation by NMR. 
 
Chapter 2: Isolation of myxovirescins was performed in collaboration with the author. 
 
Chapter 3: Myxochromid A3 was isolated and the structure was elucidated by the 
author.The structures of myxochromids A2 and A4 could be clarified by feeding 
experiments and subsequent LC-MS (MS/MS) analysis. The absolute configuration 
of the amino acids from mxyochromid A3 was determined by the author. 
 
Chapter 4: The described work was performed by the author if not indicated differently 
in the text.  
 
Chapter 5.1: The major part of the work was performed by the author (80%). 
Transposon mutagenesis was performed by Helge B. Bode. Structure elucidation was 
performed by Helge B. Bode and the author. 
 
Chapter 5.2: The major part of the work was performed by the author (80%). Detailed 
docking domain analysis was performed by Kira J. Weissman. Inactivation of dkxG in S. 
aurantiaca and synthesis of Pyrrolyl-2-carboxyl-SNAC were performed by Jeroen S. 
Dickschat. 
 
Chapter 6: The work was performed by the author in large part. Anke Göhring 
supported the HPLC-MS analysis and Michael W. Ring performed fatty acid analyses.
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Discussion: 
During the ongoing process and finally with the finishing of the genome sequencing 
project in 2006 (44), it became increasingly apparent that Myxococcus xanthus might 
be not only a suitable model organism for myxobacterial development, but also a 
proficient producer of secondary metabolites (12,13). At least 18 biosynthetic gene 
clusters could be identified, among them six nonribosomal peptide synthetases and 
12 hybrid polyketide synthase/ nonribosomal peptide synthetase systems. Four of 
these biosynthetic gene clusters were readily assigned to secondary metabolites 
already known from other myxobacterial strains, namely the myxalamids, the 
myxovirescins, the myxochelins and the myxochromides. A fifth family of natural 
products was identified in the course of this work (Figure 9). Disruption of this gene 
cluster by transposon mutagenesis as well as targeted plasmid integration led to a 
constant tan phenotype. Purification of the corresponding compounds and 
subsequent structure elucidation clarified the chemical structure of the yellow 
pigments which were named Dkxanthenes in honour of Dale Kaiser (91).   
 
Figure 9. Genomic map of M. xanthus indicating the number and type as well 
as the location of secondary metabolite gene clusters on the chromosome. 
Gene clusters that could be correlated to the produced secondary metabolite 
are indicated. 
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1. Myxalamid 
 
Myxalamids resemble a class of hybrid PKS/NRPS natural products that were first 
isolated from Myxococcus xanthus Mx x12 and which exhibit antibiotic activity 
against yeast, Gram-positive bacteria and eukaryotic cell lines (11,42,61). The 
biosynthetic gene cluster was first characterized from Stigmatella aurantiaca Sg a15 
as one of very few combined PKS/NRPS systems reported at the time (127). 
Furthermore, a novel type of chain release through reduction of the terminal PCP-
bound alanine moiety to 2-amino-propanol was described (127). Sequence 
comparison revealed the presence of a very similar gene cluster in M. xanthus 
DK1622 as well (on average over 80 % sequence identity on the DNA-level), with 
slight differences when compared to the biosynthetic gene cluster of S. aurantiaca. 
For instance, the last polyketide synthase elongation module is split into two 
separated proteins in S. aurantiaca but is encoded on one gene in M. xanthus (11). 
From the biosynthetic point of view, the most apparent difference can be observed in 
the starter unit utilization: S. aurantiaca Sg a15 produces myxalamid B as the major 
metabolite but also myxalamids C and D in easily detectable amounts, while 
myxalamid A is only produced in trace amounts. M. xanthus DK1622 in contrast 
produces myxalamid A by far as the major myxalamid metabolite besides smaller 
amounts of myxalamid B and C (Figure 10, A).  
 
Figure 10. (A) Structural myxalamid derivatives and HPLC-UV chromatograms 
of S. aurantiaca and M. xanthus; (B) Numbering of the myxalamid B carbon 
atoms of the starter unit. 
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This might be explained by a more promiscuous loading module AT domain of M. 
xanthus for larger starter units such as 2-methyl-butyryl-CoA (which is used in 
myxalamid A biosynthesis), or by an improved precursor supply of the respective 
starter unit to the myxalamid biosynthetic pathway of the respective strains. Analysis 
of the S. aurantiaca and M. xanthus AT loading domains reveal a very high homology 
but also a noteworthy difference in the specificity conferring residues (Figure 11). 
Sequence alignment analyses reveal that residues 198-201 typically exhibit an HAFH 
motif for malonate- and a YASH motif for methylmalonate extender unit selection 
(26,159). According to the selection of starter units that differ from the most widely 
used elongation units methylmalonate- and malonate-CoA, the loading domains of 
both myxalamid biosynthetic pathways differ in these motifs. Hence, they also show a 
different motif when compared to each other, with a very unusual proline residue at 
position 199 of the M. xanthus loading AT domain (Figure 11).  
 
 
Figure 11. Sequence alignment (black shading: identical amino acid residues; 
grey shading: similar residues) of loading module AT domains of Myxococcus 
xanthus (Mx) and Stigmatella aurantiaca Sg a15 (Sga). Substrate specificity 
conferring residues 198-201 are indicated by a black bar and the unusual 
proline residue is displayed by an asterisk. 
 
Remarkably, this uncommon residue is also found in the AT domain of the loading 
module in avermectin biosynthesis (55) that as well selects 2-methyl-butyryl-CoA as 
the starter unit. Thus, residue 199 might be a promising candidate for point 
mutagenesis approaches in order to shift the substrate specificity of the AT loading 
domain of S. aurantiaca towards an increased incorporation of 2-methyl-butyryl-CoA. 
However, P199 is also found in module 4 of both biosynthetic pathways and such 
might solely resemble another unusual feature of myxobacterial biochemistry that 
differs from published model systems (Table 1) (155). 
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Table 1. AT domain specificity motifs of proteins/ modules [B-F/ (L, 1-7)] for 
myxalamid biosynthetic pathways of Stigmatella aurantiaca (MxaS) and 
Myxococcus xanthus (MxaM) 
MxaFS (L) VAVH MxaFM (L) VPVH 
MxaFs (1) VASH MxaFM (1) VASH 
MxaEs (2) VASH MxaEM (2) VASH 
MxaDs (3) VASH MxaDM(3) VASH 
MxaCs (4) VPSH MxaCM (4) VPSH 
MxaCs (5) YAFH MxaCM (5) YAFH 
MxaCs (6) HAFH MxaCM (6) HAFH 
MxaBs (7) VASH MxaBM (7) VASH 
 
Despite differences in substrate specificity and quantities of substrate incorporation, 
the enzymatic machineries of both biosynthetic pathways apparently tolerate a broad 
range of short chain carboxylic acid CoA esters as starter units of the respective 
loading module. For this reason, a mutasynthetic approach (150) was applied in 
order to test for the acceptance of various carboxylic acid starter units that are 
naturally not available and thus not build into the myxalamid scaffold. In order to 
increase the production yield and to simplify the purification of potentially novel 
myxalamid derivatives, these starter units were fed to M. xanthus and S. aurantiaca 
mutants that had a defect in the bkd locus (88,89). Such mutants lack the activity of 
the branched-chain keto acid dehydrogenase that is required for the degradation of 
the branched-chain amino acids (iso-)leucine and valine to the respective branched-
chain carboxylic acids (92). Among them, 2-methylbutyryl-CoA and isobutyryl-CoA 
are used as natural precursors for myxalamid A and B biosynthesis, respectively, and 
a decreased quantitiy of these starter units would consequently lead to the depletion 
of the particular metabolites. This approach was readily performed in the generation 
of novel avermectin derivatives (29,55).  
Unexpectedly, both M. xanthus and S. aurantiaca bkd mutants retained the ability to 
produce myxalamid B (with isobutyryl-CoA as the starter unit), although at a reduced 
production level when compared to the wild type. In M. xanthus bkd mutants, a 
second form of Bkd activity is responsible for the biosynthesis of isobutyryl-CoA 
derived from valine as could be shown by feeding experiments with [D8]-valine. S. 
aurantiaca bkd mutants instead use this pathway to a lesser extend when compared 
to the wild type but rather employ an alternative biosynthetic pathway branching from 
the mevalonic acid isoprenoid biosynthesis (11,88,89). This pathway has already 
been described for the biosynthesis of iso fatty acids in S. aurantiaca bkd mutants 
Discussion 
51 
(89), and in myxalamid biosynthesis the isobutyryl-CoA starter unit is supplied by α- 
and β-oxidation of iso-odd fatty acids as was shown by feeding experiments.  
The incorporation pattern of [2-13C]-acetate was determined by NMR analysis after 
feeding of the precursor and purification of myxalamid B from the respective strains. 
Only the S. aurantiaca bkd mutant shows a significant labelling of carbons C-15, C-
17 and C-19 (for numbering, see Figure 10, B), as it is expected for HMG-CoA 
derived isobutyryl-starter units (Figure 12, myxalamid B labelling pattern from M. 
xanthus strains correlates with the one obtained for S. aurantiaca wild type).  
 
Figure 12. 13C NMR analysis of myxalamid B from (A) S. aurantiaca wild type 
and (B) S. aurantiaca bkd mutant after feeding of [2-13C]-acetate. Increased 
signals for C-15, C-17 and C-19 in the bkd mutant are indicated. 
 
For mutasynthesis, altogether 19 carboxylic acids that were naturally not used as 
starter units for myxalamid biosynthesis were fed to cultures of M. xanthus and S. 
aurantiaca bkd mutants. Indeed, nine novel myxalamid derivatives (which were 
named MS-1 to MS-9) were produced and accounted for up to 60% of the total 
myxalamids produced from the strain (11). As a proof of principle, two of these novel 
non-natural secondary metabolites (carrying a cyclopropyl- or cyclopentyl-starter unit, 
respectively) were chosen for isolation from the M. xanthus bkd strain and 
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subsequently their structures were confirmed by one- and two-dimensional NMR 
analysis (71). 
Meanwhile M. xanthus produces all novel derivatives MS-1 to MS-9 after feeding of 
the respective precursor, S. aurantiaca produces only compounds MS-6 to MS-8. 
One explanation might be a higher flexibility of the intrinsic acyl-CoA ligase of M. 
xanthus when compared to the CoA ligase of S. aurantiaca. Alternatively, or in 
addition, this finding indicates again that the M. xanthus loading AT domain might be 
more flexible especially towards larger starter units, a hypothesis which is supported 
by the higher yield of myxalamid A relative to all other myxalamids produced in this 
strain. Myxalamids thus seem to be a feasible system for further investigations 
aiming at alterations of starter unit selection, be it by point mutagenesis, domain or 
whole module swap experiments. 
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2. Myxovirescin 
 
Myxovirescins are a family of compounds with antibiotic activity, primarily against 
Gram-negative bacteria. They were first isolated from Myxococcus virescens Mx v48 
and have to date been found exclusively in the genus Myxococcus (40,141,142). 
Simunovic et al. could show that at least two members from this family of compounds 
were produced from M. xanthus DK1622 as well, myxovirescin A and C (Figure 13) 
(131). 
 
Figure 13. Myxovirescin A: R = O, myxovirescin C: R = H, H 
 
Myxovirescin biosynthesis gives another interesting example for myxobacterial 
biosynthetic machineries that differ from textbook logic. Among these is the discovery 
of an AT-less (23) multimodular PKS system that is fed through the trans-acting AT 
domain TaV as well as the incorporation of rarely used β-alkyl moieties into the 
myxovirescin scaffold by an enzyme complex employing an HMG-CoA-like synthase. 
Detailed information about myxovirescin biosynthesis can be found in (128-131). 
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3. Myxochromid 
 
Myxochromids (Figure 14) are a family of compounds that were originally isolated 
from Myxococcus virescens Mx v48 (139), and no biological function could be 
assigned to these metabolites so far. Besides myxochromids from the subfamily A 
which are produced from several Myxococcus species, myxochromids S that exhibit 
small but conspicuous structural differences to the A family were recently isolated 
from S. aurantiaca DW4/3-1 (Figure 14, A) (152). This paved the way for a detailed 
analysis of commonalities and in particular of the differences of both biosynthetic 
pathways (153). 
In the scope of this work, myxochromid A3 was isolated from M. xanthus DK1050 and 
its structure was elucidated by one- and two-dimensional NMR analysis. The original 
published structure (139) of these lipohexapeptides could be revised such that the α-
carboxyl group of a glutamine rather than the γ-carboxyl group of a glutamate residue 
forms the ester linkage with the hydroxy group of the N-methylated threonine moiety 
(Figure 14, B and C). The structures of myxochromids A2 and A4 could be assigned 
by HPLC-MS and MS/MS experiments in combination with feeding experiments 
employing [13C4,15N1]-L-threonine that lead to a specifically labelled threonine-
polyketide side chain MS/MS fragment (153). 
 
Figure 14. (A) Myxochromid S; S1: R = Me, S2: R = Et, S3: R = CH=CH-Me     
(B) Myxochromid A; A2: R = Et, A3: R = CH=CH-Me, A4: R = CH=CH-Et             
(C) Structure of the originally published myxochromid A  
 
Discussion 
55 
The myxochromid A and S megasynthetases are composed of seven biosynthetic 
modules. The first module resembles the only PKS present in both assembly lines, 
and heterologous expression experiments unambiguously demonstrated that this 
PKS acts iteratively with the intrinsic capacity to produce polyketide chains of varying 
lengths (151,152). Surprisingly, the length of the primarily processed polyketide 
chains in M. xanthus and S. aurantiaca differs as myxochromids A carry a 17-19 
carbon atom side chain wherease myxochromids S harbour a 16-18 fatty acid 
extension (Figure 14, A and B), implying a differing intrinsic control of the number of 
iterations applied in both systems and/ or a differing preference of both biosynthetic 
pathways in starter unit selection (acetate-CoA vs. propionate-CoA).  
Determination of the absolute configurations of the amino acids incorporated into 
myxochromid A revealed that all amino acids except alanine exhibit the L 
configuration. For alanine, both L and D configured amino acids were assigned in 
equal amounts which correlates well with the results for myxochromid A from 
Myxococcus virescens Mx v48 (139). Analysis of the biosynthetic gene cluster makes 
the structure shown in Figure 14 (B) the most likely candidate since module 2 
(incorporating alanine in myxochromid A biosynthesis) comprises an epimerization 
domain that catalyzes the conversion from L- to D-configured amino acids (84,153). 
In contrast, all amino acids of myxochromid S were assigned as L-configured. 
Furthermore, the peptide core of myxochromids S consists only of five amino acids 
instead of six as observed for myxochromids A, with the proline moiety missing and 
the order of alanine and leucine switched in myxochromid S relative to myxochromid 
A.  
Wenzel et al. demonstrated that point mutations of the respective A domains led to 
the shift towards selection of differing amino acids rather than by genetic exchange of 
the particular A domain or the complete modules. Intriguingly, the C domains of the 
respective modules appear to be flexible to a certain degree and fail to perform their 
gatekeeper role in accepting only one specific incoming intermediate. On the other 
hand, further (point) mutations might have led to changes in C domain discrimination 
abilities of the respective module allowing the assembly using an alternativel amino 
acid residue.  
More strikingly, myxochromid S biosynthesis constitutes the first example for the 
skipping of a complete NRPS module as could be shown by in vitro experiments. 
Expression of the carrier protein domains from modules 4 of the myxochromid A and 
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S biosynthetic pathways, respectively, and coexpression of the 4’-
phosphopantetheinyl transferase MtaA activated the myxochromid A carrier protein 
but not the myxochromid S carrier protein. The flexibility in substrate activation and 
recognition as well as the obvious tolerance towards point mutations that alter 
domain specificities or even abolish their function makes the myxochromid 
biosynthetic pathway a promising system for further investigations aiming at site-
directed mutagenesis and domain or module swaps of both biosynthetic pathways 
(119). 
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4. Myxochelin 
 
Myxochelins (Figure 15) are siderophores of the catecholate-type that were first 
characterized from the myxobacterium Angiococcus disciformis An d30 (77). It did 
not take a long time until they became apparent to be generally used small molecules 
for iron-uptake among the myxobacteria (besides the hydroxamate-type siderophore 
nannochelin from Nannocystis exedens Na e483 (79)). Recently, myxochelin A was 
isolated from the actinomycete Nonomuraea pusilla TP-A0861 (94) indicating that 
myxochelins might be widely used as siderophores in the bacterial world. The gene 
cluster for myxochelin biosynthesis was described from Stigmatella aurantiaca Sg 
a15 (126). Mutants defective in myxochelin biosynthesis had to be supplemented 
with Fe(III) in order to grow, emphasizing the essential role of the myxochelins in 
iron-homeostasis. Furthermore, inactivation of the myxochelin biosynthetic gene 
cluster in M. xanthus was not possible when standard inactivation conditions were 
applied (Socorro D.J.Cortina, N., not published). Here, supplementation with Fe(III) 
will most likely support a more successful approach. Myxochelin biosynthesis 
employs an unusual two-fold usage of a condensation domain that attaches two 2,3-
dihydroxy benzoic acid moieties to the α- and the ε-amino group of L-lysine, 
respectively (37). The readily processed natural product is finally released from the 
thio-template by the rarely found reductive release mechanism as was subsequently 
described for myxalamid biosynthesis as well. Myxochelin B is produced from 
myxochelin A most presumably via an aldehyde intermediate (126). Strikingly, 
myxochelin biosynthesis could be reconstituted in vitro by expression of the 
respective biosynthetic enzymes in presence of the necessary precursors and co-
factors (37). Besides a weak antibacterial activity against several Gram-positive 
bacteria described in the original report of Kunze et. al (77), Miyanaga et al. 
discovered a weak cytotoxic activity and, more promising, a potent in vitro inhibition 
of tumor cell invasion at concentrations that did not show any cytotoxic acitivity (94).  
The hereby described discovery of a novel 3’’-O-methylated myxochelin A derivative 
from M. xanthus within an acitivity-guided approach aiming at the isolation of the 
cytotoxic principle of M. xanthus cell/ XAD-extracts might possibly have been guided 
by this novel reported cytotoxicity of the myxochelins. Yet, it remains to be 
questioned whether myxochelins resemble the actual cytotoxic principle of the 
extracts, considering the stronger cytotoxic activity of myxalamides (11) as well as 
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further putative compounds that might be active at concentrations in which they are 
not even detectable with standard analytical chemistry methods. 
The drastic effects of the inactivation of the myxochelin biosynthetic pathway in S. 
aurantiaca and M. xanthus (which was not possible, see above) rather suggest that 
these metabolites truly are the iron-chelating natural products of these strains. 
Proteins known to be responsible for the uptake of Fe(III)-siderophore complexes 
such as TonB-dependent receptors (50) are encoded in the genome of M. xanthus 
(data not shown) and make it likely that siderophore secretion and reuptake takes 
place in a similar manner as reported for well-investigated siderophore systems like 
enterobactin in E. coli. Concerning iron-release from the Fe(III)-siderophore complex, 
nothing is known for myxobacteria so far. The actively driven methylation (71) of one 
meta-hydroxy group of the myxochelins most presumably destroys the catecholate 
Fe(III)-siderophore complex, and, if at all, only the weaker salicylate complex can be 
formed. For the enterobactin system, such an (artificially) induced shift through 
protonation towards the salicylate coordination (1) was shown to make the reductive 
release of Fe(II) from the complex much more favourable. Methylation in comparison 
to protonation of the meta-hydroxy group leads to a non-pH dependent shift that is 
not reversible and which appears to be better to control by induction of a 
methyltransferase than by the reversible transfer of a proton. Thus, the discovery of 
3’’-O-methylmyxochelin A might have opened the door for further insights into 
siderophore-mediated iron homeostasis in (myxo-)bacteria. Enzymes involved in 
iron-uptake and –release that are only found in bacteria certainly are interesting 
targets for future antibiotic research. 
 
Figure 15. (A) Structure of myxochelin A and B (A: R = OH, B: R = NH2) and (B) 
the newly identified 3’’-O-methylated myxochelin A derivative 
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5. DKxanthene 
 
The DKxanthenes (Figure 16) constitute the first and so far sole family of 
compounds that was primarily reported from M. xanthus DK1622 (91). They appear 
to be characteristic for M. xanthus, since strains from various differing locations 
worldwide invariably produce these metabolites (74). Yet, as could be demonstrated 
during this work, they are produced from other myxobacterial species (at least S. 
aurantiaca) as well and thus are not suitable as chemotaxonomic marker for M. 
xanthus. DKxanthenes are prominently represented within the cells and are not 
secreted to the medium, as was observed during the course of isolation of these 
metabolites (91). Isolation was severely hampered due to unfavourable 
chromatographic properties, the presence of several derivatives that had to be 
separated from each other and the tendency of these metabolites to appear as 
double-peaks, which even occurred during the ongoing separation process. The 
latter is most likely caused by cis-trans isomerization of one (or multiple) double 
bond(s) of the polyketide chain. Consequently, the purification required several 
sequential separation steps and was performed in the dark whenever possible to limit 
isomerization (and even degradation) during the workup (91). Finally, sufficient 
amounts of DKxanthene-534 and DKxanthene-560 were obtained for detailed one- 
and two-dimensional NMR analysis. Further metabolites were identified in M. xanthus 
extracts and their structures were determined by mass spectrometric analysis (MS 
and MSn) in combination with feeding experiments employing [13C4, 15N1]-threonine 
and [D6]-propionate (91) (Figure 16).  
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Figure 16. DKxanthene structures determined from M. xanthus and S. 
aurantiaca. Presence of the respective derivative in each strain is indicated by 
checkmarks. Numbering of atoms is shown at the structure. 
 
As observed for other polyenes, NMR structure elucidation of the conjugated double 
bond system was complicated due to signal overlap, and no clear assignment of 
coupling partners and coupling constants was possible. Here, changing the 
deuterated NMR-solvent system from DMSO to methanol and methanol/ benzene 
mixtures of differing composition allowed a more clear assignment, and in 
combination with the obtained UV-data and calculation of theoretical chemical shifts 
an all-trans configuration was proposed for the polyene chain (91) (Figure 17).   
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Figure 17. Selected 1H-NMR spectra of DKxanthene-534 applying different 
deuterated solvent systems (given in the upper right corners). Numbers above 
the signals indicate the corresponding proton. Signals were shifted under 
different solvent conditions and hidden coupling constants were released as 
indicated. 
 
The DKxanthene biosynthetic gene cluster was first discovered in M. xanthus 
DK1622, and shortly after that in S. aurantiaca DW4/3-1 as well, enabling the 
informative comparison of both biosynthetic pathways. As can be readily proposed 
from the structure of the DKxanthenes, the biosynthetic gene cluster encodes a 
hybrid PKS/NRPS megasynthetase. The production of a broad natural diversity 
which is restricted to specific parts of the molecule seems to be a characteristic 
feature for DKxanthene biosynthesis. Meanwhile the structures of the starter unit, the 
oxazoline ring and the presence of a terminal asparagine moiety are unvaried in all 
derivatives known so far, the architecture of the polyene chain is more flexible with 
respect to its length and methylation pattern. Furthermore, the asparagine moiety is 
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hydroxylated in the main but not all derivatives in M. xanthus, and none hydroxylated 
metabolites were identified in S. aurantiaca (Figure 16).  
The latter is most likely due to the absence of dkxD in the biosynthetic gene cluster of 
S. aurantiaca (dkxDW), which encodes a FAD-dependent monooxygenase in the M. 
xanthus cluster (dkxDK) (Figure 18, A).  
 
Figure 18. (A) DKxanthene biosynthetic gene clusters of M. xanthus and S. 
aurantiaca. Genes encoding enzymes involved in starter unit biosynthesis 
(dark grey), hydroxylation (black), PKS formation (hatched) and NRPS 
(chequered) biochemistry are indicated. (B) Model for DKxanthene 
biosynthesis. The pyrrole carboxylic acid starter unit is derived from proline 
and processed as described recently (147). Four PKS modules perform 
altogether at least six rounds of chain extensions (and seven in the case of 
DKxanthene-534 as shown). DkxN appears to be the best candidate for 
programmed iteration, and DkxG might iterate in a randomly occurring 
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process. Notice the different order of enzymes when compared to the order of 
genes in the DKxanthene gene cluster. 
 
One common characteristic of type I polyketide biochemistry is the colinearity of 
biosynthetic enzymes with the chemical structures generated from the multimodular 
machinery. This colinearity rule is not absolute, however, and examples exist in 
which single modules within type I PKS systems were used more than once. So far, 
one single module was always shown or postulated to be responsible for this 
programmed or aberrant iteration (4,38,48). Iteration is proposed for DKxanthene 
biosynthesis, since altogether four PKS modules assemble the polyketide chain that 
requires at least one and up to four repetitive uses of at least one module. 
Alternatively, extra PKS modules might be located elsewhere in the genome, an 
option that can not be ruled out by the chosen approach (here, successful 
heterologous expression of the DKxanthene cluster is required for unambiguous 
proof). Yet this option appears to be unlikely as there is no precedent for such a 
case, and second, docking domain analysis (113) hints to the well assorted 
arrangement of DKxanthene modules DkxG, DkxN, DkxH, DkxI and DkxJ (Figure 18, 
B). This order might as well reason the observed pattern of DKxanthene derivatives 
since the docking domain interaction of DkxG and DkxN appears to be not as 
optimized as the others, possibly providing a basis for the postulated programmed 
iterative usage of DkxN and the possible aberrant iterative use of DkxG.  
The DKxanthenes were tested for their therapeutic potential in antibacterial (Gram-
positive and –negative), antifungal and cytotoxicity assays. However, in none of the 
tests applied a mentionable activity was observed (data not shown). Rather, as these 
metabolites remain within the cells and since earlier reports (18,82,124) indicated the 
involvement of the yellow pigments in developmental processes of M. xanthus, we 
set out to determine a potential role of the DKxanthenes for the producing organism 
itself. First, mutants defective in DKxanthene biosynthesis were tested for fruiting 
body formation in comparison to their parent wild type strain M. xanthus DK1050. 
The build-up of fruiting bodies was observed for all mutants tested, but an apparent 
delay in aggregation and completion of fruiting body formation indicated that the 
developmental process is hampered in absence of DKxanthenes. The formation of 
refractile spores was confirmed after 72 hours of development (Figure 19). 
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Figure 19. (A) M. xanthus DK1050 wild type and (B) DKxanthene-negative 
mutant derived thereof after 72h of development, after resuspension. 
Remaining vegetative cells/peripheral rods are rod-shaped, and spores are 
round and refractile. 
 
Unexpectedly, when spores of wild type versus mutant were tested for viability after 3 
days of development (after ultrasound and heat treatment), no viable spores could be 
recovered from the mutants. Testing of ongoing time-points during development 
revealed that this defect persisted until day seven, and altogether a maximum 
recovery rate of 25% of viable spores was observed when compared to the wild type. 
However, this defect could be complemented at least in part by codevelopment of the 
mutant strains with wild type, and, moreover, by the addition of purified DKxanthene-
534 to the developing cells (91). Similar results were obtained in preliminary studies 
that dealt with the phenomenon of phase variation: M. xanthus cells are able to 
alternate between two colony types. The first and usually predominant phase is 
characterized by the yellow pigmentation and rough, swarming colonies (yellow 
phase). In the alternate phase, the cells are tan and mucoid with smooth edges (tan 
phase). Both phases are interconvertible. Mutants that are locked in the tan phase 
were very inefficient in fruiting body formation and unable to produce heat- and 
sonication-resistant spores. However, when mixed with predominantly yellow 
cultures, the spores produced from these mixtures were derived predominantly from 
the phase-locked tan mutants (82). 
DKxanthenes resemble in large part polyenes, a class of metabolites that very often 
exhibit protective properties against various damaging agents including free radicals, 
and since an UV-protective effect of the yellow pigments as well as the UV-induced 
conversion of tan cells to yellow cells was described before (18), the antioxidative 
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potential of DKxanthene-534 was determined in two test systems. The strung-out 
structure and a large lipophilic part with a hydrophilic “C-terminal” hydroxy-
asparagine moiety make it likely that the DKxanthenes are located within the 
membrane, where they could play a similar role in protecting fatty acids from 
oxidation and furthermore in rigidifying the membrane to maintain the required 
membrane fluidity as was described before for carotenoids, members of a family with 
similar polyene structure (46). Indeed, an antioxidative activity could be assigned to 
the DKxanthenes, supporting this hypothesis. Yet, it remains questionable whether 
this activity is a sufficient explanation for all of the effects observed during 
development, and it appears rather likely that pleiotropic effects lead to the overall 
phenotype.   
Thus, the phenotype of DKxanthene-negative mutants was further investigated by 
electron microscopy (performed by Dr. Jan Hegermann) and proteomic studies 
(performed by Dr. Yasser Elnakady). In short, wild type and mutant cells were 
developed in submerged culture or on nutrient-deficient agar, harvested at selected 
time points and prepared for the subsequent analysis. 
Electron micrographs allowed insights into the defect of DKxanthene-deficient 
myxospores. Meanwhile, no apparent difference was observed for vegetative cells, 
developmental spores of the mutants differ in size and morphology from the wild 
type. Spores from DKxanthene-negative mutants are slightly but unambiguously 
larger than wild type spores, a difference that is more significant after 72 hours of 
development but that is still existent after 5 days. Furthermore, lipid droplets within 
the spores are smaller in size but larger in number in the mutant, and retain longer 
within the myxospores during development. Finally, apparent differences exist with 
respect to spore cortex and coat that both consist of several layers (136). 
DKxanthene-negative mutants produce spores with less condensed and less defined 
spore cortex and coat (Figure 20). 
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Figure 20. Electron micrographs of (A) wild type and (B) DKxanthene-negative 
mutant spores after 72 hours of development. The presence of lipid droplets is 
indicated by asterisks. 
 
A very similar effect was observed in spores that were induced by the addition of 
glycerol. Glycerol-induced sporulation is independent from fruiting body formation 
and appears already after 2 hours time of induction (31) (Figure 21). 
 
 
Figure 21. Electron micrographs of (A) wild type and (B) DKxanthene- negative 
mutant spores derived from glycerol-induction. 
 
This indicates that maturation of the mutant spores is at least delayed, and 
furthermore a direct or indirect involvement of the DKxanthenes in lipid metabolism 
seems likely, e.g. by emulsifying lipids from the lipid droplets that are further 
processed during the reorganization that takes place during spore’s maturation (114). 
For proteomic analysis, a two-dimensional fluorescence difference gel 
electrophoresis (2D DIGE) approach with subsequent MALDI-TOF peptide 
identification was chosen. Here, two samples can be compared to each other within 
one gel, and different labelling of the respective proteins allows the differential in gel 
detection as well as comparison of both samples without further treatment of the gel. 
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Four parallel samples of wild type versus mutant were analyzed that way under 
vegetative as well as developmental conditions (Meiser and Elnakady, unpublished).   
For vegetative cells (= time-point 0h of development), altogether nine proteins were 
detected that appeared to be differentially expressed (taken a ratio of a more than 
1.5-fold increase resp. decrease in protein expression in all four samples as cutoff) 
(Table 2). Eight of them were up- and one was down-regulated in the DKxanthene-
negative mutant. Unfortunately, identification succeeded only for five of the up-
regulated proteins. These include a dehydrogenase (glucose/ sorbosone family), the 
glycine cleavage system T protein, a FG-GAP repeat protein, FibA and ProV. Among 
the proteins identified, especially the three latter appear to be interesting findings. 
FibA represents the most abundant (known) extracellular matrix-bound protein that 
shows homologies to M4 zinc metalloproteases, was proven to be important for 
stimulation of cells by the chemoattractant phosphatidylethanolamine (PE) and for 
formation of discrete aggregation foci (17,69). Yet, although FibA resembles a protein 
known to be involved in developmental processes and is thus a promising candidate 
for the interpretation of the effects caused by the absence of DKxanthenes, its 
quantification by proteome analysis was observed to be not perfectly reliable (in 
former experiments employing M. xanthus wild type and different mutant strains) and 
thus makes the interpretation of this finding difficult (Y. Elnakady, M.O. Altmeyer, 
personal communication). However, another protein that typically interacts with 
extracellular matrix proteins is up-regulated in the mutant as well: FG-GAP repeat 
proteins constitute a family of proteins that are predicted to fold into a ß-propeller 
domain. Such domains were reported to be part of phosphatidylinositol 
phospholipase D as well as integrins and contain FG (phenylalanyl-glycyl) and GAP 
(glycyl-alanyl-prolyl) consensus sequence repeats (132). Integrins are cell adhesion 
molecules found in eukaryotes, and cell adhesive events are mediated by 
transmembrane receptors that regulate adhesion, embryonic development by 
controlling cell migration, growth and differentiation (85). Integrins bind to diverse 
ligands from the extracellular matrix and cell surface receptors.  One might therefore 
speculate that one such ligand might be FibA. The binding of invasins from 
enteropathogenic bacteria to integrins allows the internalization into the eukaryotic 
host cell (58). Binding to ligands is dependent of divalent cations and acidic residues 
were identified as key components of integrin-binding ligands (85). Only one protein 
in the databases shows high homologies to MXAN_1005, a FG-GAP repeat protein 
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from S. aurantiaca DW4/3-1 (58% identity/ 72% similarity). Much less significant 
homologies are found for the described eukaryotic integrin family of proteins.  
ProV represents a homologue of OpuAA, the ATP-binding/hydrolyzing subunit of an 
osmoregulated ABC transporter system (OpuA) (143). It was shown for Lactococcus 
lactis that OpuA can act both as osmosensor and osmoregulator. Experiments 
employing artificial phospholipid bilayers suggested that OpuA is activated by 
sensing changes in the physical status of the lipid bilayer via lipid/protein interactions 
(143). The upregulation of ProV might therefore be another indicator for the affected 
integrity of the cell membrane of DKxanthene-negative mutants as well as for the 
membrane-associated localization of the DKxanthenes.  
MXAN_2249 (ProV) and MXAN_1005 (FG-GAP repeat protein) were inactivated by 
plasmid insertion mutagenesis and tested for fruiting body formation. Both mutants 
retained the ability to produce fruiting bodies (data not shown). Closer inspection of 
both strains is currently under investigation in our laboratory.  
 
Table 2. Differentially expressed proteins identified in vegetative cells of wild type and 
DKxanthene-negative mutants (Up- or down-regulation of proteins refers to the mutant in 
comparison to the wild type) 
Gene name/ MXAN Gene product Regulation 
MXAN_6745 Dehydrogenase, glucose/ sorbosone 
family 
2.60 up 
gcvT/ MXAN_3040 
 
Glycine cleavage system T protein 1.74 up 
MXAN_1005 FG-GAP repeat protein 2,63 up 
fibA/ MXAN_6106 Matrix-associated zinc 
metalloprotease FibA 
1.76 up 
proV/ MXAN_2249 Glycine betaine/ L-proline ABC 
transporter, ATP-binding protein 
1.96 up 
 
Differences in proteome pattern strongly increased after 24 hours of development. 
Altogether at least 28 proteins were differentially regulated, and 19 proteins were 
down- and nine proteins up-regulated. Among them, 12 could be identified (Table 3). 
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Table 3. Differentially expressed proteins of wild type and DKxanthene-negative mutants 
identified after 24 hours of development (Up- or down-regulation of proteins refers to the 
mutant in comparison to the wild type) 
Gene name/ MXAN Gene product Regulation 
MXAN_7110 Peptidyl-prolyl cis-trans 
isomerase, FKBP-type 
1.58 up 
MXAN_5430 Development-specific protein S 
(Spore coat protein S) 
1.66 up 
MXAN_6451 Hypothetical protein 1.73 up 
MXAN_6035 2-oxoglutarate dehydrogenase, 
E1 component 
1.77 down 
MXAN_6911 TonB-dependent receptor 1.93 down 
MXAN_2408 Translation elongation factor G  1.50 down 
pckG/ MXAN_1264 Phosphoenolpyruvate 
carboxykinase   
1.50 down 
MXAN_5856 Acetate-CoA ligase  1.63 down 
MXAN_5266 Hypothetical protein 1.50 up 
MXAN_3068 Translation elongation factor Tu 1.53 up 
MXAN_3434 Hypothetical protein 2.12 up 
MXAN_4863 Adventurous gliding motility 
protein AgmK 
2.33 down 
 
One peptidyl-prolyl cis-trans isomerase is among the identified proteins, which is 
upregulated in the mutant strain (MXAN_7110) (a second peptidyl-prolyl cis-trans 
isomerase (MXAN_6153) that is down-regulated (1.86 down) in the mutant was 
identified as well but needs to be reconfirmed). Besides the role of these enzymes in 
prolyl cis-trans isomerization during protein folding, recent studies have uncovered 
that prolyl-isomerization can also function as a molecular timer in a number of 
biological and pathological processes, including cell signalling, gene expression and 
infection (86). Consequently, it appears within the realms of possibility that the 
identified enzymes could play a role in triggering cell differentiation at specific time 
points during development. The differential regulation of two enzymes of this class at 
contrastive levels might be due to the delayed developmental progession of the 
DKxanthene-negative mutants. Mutants defective in these enzymes might possibly 
be unable to develop or might arrest at specific time points during development. 
Unfortunately, disruption of both genes by plasmid insertion did not succeed, 
indicating that they are essential for cell viability.  
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The most significantly down-regulated protein AgmK represents another remarkable 
finding. It is part of the adventurous gliding motility apparatus, one of two known 
motility systems (A and S) in M. xanthus (64,93) that are separated from each other 
but that are used as coordinated motility engines. Even though no significant 
differences for A- and S-motility were observed for DKxanthene-negative mutants in 
comparison to the wild type (91), the decreased production of A-motility proteins 
might be one reason for the reported differing colony morphology of tan phase 
variants. 
Three enzymes involved in primary metabolism (MXAN_6035, MXAN_1264 and 
MXAN_5856) are identified as down-regulated in the mutants at comparable level. 
The formation of myxospores involves the remodelling of the peptidoglycan layer, 
with the amount of peptidoglycan increasing relative to the surface area during the 
metamorphosis from rod-shaped vegetative cells towards the spherically shaped 
spores. Furthermore, novel spore envelope polysaccharides are synthesized, and 
trehalose production strongly increases during sporulation (122). Thus, 
gluconeogenesis is extended during the sporulation process, giving further evidence 
for a delayed or hampered mature spore formation in the DKxanthene-negative 
mutants. It is worth mentioning that a functionally similar protein to MXAN_1264 (a 
phosphoenolpyruvate carboxykinase, a key enzyme for gluconeogenesis), PykA from 
S. aurantiaca (a pyruvate kinase, involved in glycolysis) was identified as “indole-
binding protein” essential for fruiting body formation (133). 
Protein S, the most abundant and development-specific protein of M. xanthus, 
however, is upregulated in the mutant strain. This appears to contrast with the 
phenomena described so far, but two possible explanations might be adduced. First, 
the overproduction of protein S might be a counter-reaction of the defective spores to 
compensate for the unusual architecture of the spore coat. The function of protein S 
during sporulation is not yet known, but some data suggest that protein S might 
function as a cement that holds the spores together within the fruiting body (67). 
Second, the higher quantities of protein S in the mutant protein extract are due to an 
intrinsic property of protein S as well as the analytic method used. Protein S 
synthesis starts early in development and the protein first accumulates in the soluble 
fraction of the cytoplasm. Later in development (15 to18 h), it can be found in the 
periplasm as well, from where it is assembled into the spore coat starting at 24 to 30 
hours of development. It was speculated that the production of protein S and its 
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retention in the cytoplasm before transport across the cytoplasmic membrane must 
occur since cells were unable to produce the massive amount of protein S 
immediately before spore formation (transport might be accomplished by a 
developmentally regulated transport protein, or alternatively, by major changes in the 
cell membrane that allow protein S to transverse the membrane) (99). As the applied 
2D DIGE approach is very suitable for soluble proteins but in contrast less applicable 
for the reliable detection of membrane proteins, the observed results might again 
mirror the retarded maturation of the DKxanthene-negative spores. Meanwhile a 
certain proportion of protein S is assembled into the spore coat of M. xanthus wild 
type after 24 hours – and thus is detracted from detection - the major part of this 
protein is still accumulated in the cytoplasm in the case of the mutants, giving rise to 
a seemingly higher yield of protein S in the DKxanthene-negative mutants. 
In summary, our data suggest that DKxanthene-negative mutants form fruiting bodies 
and spores, but the progession of this process is at least delayed, if not impaired in 
general. The underlying mechanism appears to be complicated, which is not 
surprising considering the complex biochemical changes that must occur within the 
developing cells. Moreover, the scenario should be even more complicated for tan 
phase variants as the tan phenotype should be induced by a regulatory network that 
controls the behaviour of a single cell within millions of congeners that pass through 
the developmental program.  
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6. Other (putative) natural products from M. xanthus and activation 
of carrier proteins from secondary metabolite biosynthetic 
pathways 
 
As described, the genome sequence of M. xanthus DK1622 indicates the potential of 
this strain to produce at least 18 different secondary metabolites. Five of these could 
be characterized at least in part within this work. It appears unlikely that the 
remaining biosynthetic gene clusters do not serve any function for the organism since 
maintaining the genetic information requires energy and the loss of non-functional 
gene clusters would be the expected consequence. However, no additional 
secondary metabolite was discovered in M. xanthus extracts so far except for one 
compound with a molecular mass of 582 that was identified in M. xanthus extracts 
and which is only generated and recovered reproducibly if cultivation is performed in 
presence of XAD-2 adsorber resin (unpublished observation). Several explanations 
might be adduced: First, most simple but as well very likely, the metabolites might not 
be produced under laboratory conditions which are quite remote from the conditions 
of the natural habitat of the bacteria. The induction of specific biosynthetic pathways 
might require environmental “signals” such as various nutrients, shifts in temperature, 
oxygen supply, pH or moistness, and even the competition with other microbes in the 
soil. In contrast, laboratory conditions are set up in order to be highly reproducible, 
including constant temperatures, pH and, of course, sterile conditions that only allow 
the strain of interest to grow. Assuming that all natural products have a biological 
function for the producing organism by acting as signalling or regulatory molecules 
within cells or cell communities to maintain homeostatic conditions (25), it might be 
possible that they are superfluous in standard laboratory environment. Alternatively, 
at least some of the secondary metabolites are produced even under laboratory 
conditions, but at concentrations which do not allow any analytical detection or which 
make it difficult to differentiate between background noise and the signal of the small 
molecule. This hypothesis is supported by recent investigations into the proteome of 
M. xanthus applying a two-dimensional chromatographic separation of tryptic 
peptides from M. xanthus protein lysate with subsequent mass spectrometric 
analysis (117). This approach readily allows identification of high-molecular weight 
PKS and NRPS proteins, and among them, not only proteins from biosynthetic 
pathways associated with the production of known natural products were detected 
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but also proteins from six biosynthetic gene clusters with so far unknown products. 
The presence of all biosynthetic proteins of the respecitve gene cluster is of course 
the prerequisite for biosynthesis, but appears to be likely with respect to the above 
mentioned criterion of modest energy house keeping. Statistical approaches such as 
principle component analysis (PCA) (75) help to unveil the production of secondary 
metabolites that are produced only in trace amounts, e.g. by comparing the wild type 
strain with mutants defective in one particular biosynthetic pathway (74). 
A further problem to overcome besides low production yields is featured by the 
complex media in which the bacteria are cultivated. They provide a strong 
background of signals that have to be discriminated against the “true” natural 
products, and even matching of the pure media extracts (background) against the 
bacterial culture grown in media from the same batch might be misleading since the 
non-natural product background changes during fermentation due to degradation of 
media components as well as cell lysis (Figure 22, A and B). The best comparison 
for background subtraction would thus be a bacterial culture grown in production 
medium that does not produce any secondary metabolites. Encouraged from results 
of inactivation experiments of mtaA in S. aurantiaca DW4/3-1 (36,125) leading to the 
complete abolishment of known secondary metabolite production in this strain, a 
similar approach was chosen for M. xanthus. MtaA from S. aurantiaca DW4/3-1 
represents a 4’-phosphopantetheine transferase (PPTase) with broad substrate 
specificity from the Sfp-type (95) essential for activation of carrier proteins of 
secondary metabolite biosynthetic pathways. A PPTase (MXAN_3485, renamed to 
MxPpt1) with very high sequence homology to MtaA was identified in M. xanthus and 
inactivated. Unexpectedly, the inactivation did not lead to a complete loss of natural 
product formation but rather to significant changes in the metabolite pattern (Figure 
22, C).  
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Figure 22. Base peak chromatograms (BPC) of (A) CTT medium (B) M. xanthus 
DK1050 grown in CTT and (C) the mutant in which MxPpt1 is inactive in CTT.  
Metabolites are indicated by numbers: 1 Myxochelin, 2 DKxanthene, 3 Lyso-PE 
(a species of lipids (6)), 4 Myxovirescin, 5 Myxalamid, 6 Myxochromid 
 
Subsequent analysis of the M. xanthus genome revealed the presence of another 
Sfp-type PPTase (MXAN_4192, renamed to MxPpt2) and (as expected) one AcpS-
like PPTase (MXAN_4350, renamed to MxAcpS). AcpS-like PPTases are thought to 
activate fatty acid synthases and type II polyketide synthases. Disruption of MxAcpS 
as well as the creation of a MxPpt1/ MxPpt2 double mutant did not succeed, but the 
inactivation of MxPpt2 and overexpression of MxPpt1 and MxPpt2 led to further 
insights into the roles of both enzymes in secondary metabolite production. In short, 
apparently both enzymes are necessary for the proper activation of all (known and 
analyzed) natural product biosynthetic pathways and are able to complement at least 
in part the loss of function of each other. Furthermore, both enzymes appear to be 
specific for certain biosynthetic pathways. This interpretation is exemplified in the 
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case of the mxPpt1 inactivation mutant by the resulting strong decrease in 
DKxanthene and myxovirescin production and the increase in myxalamid production 
(the latter most presumably due to increased precursor supply caused by the 
decreased competition from other biosynthetic pathways). Remarkably, a change in 
fatty acid profile was observed in all PPTase mutants as well when compared to the 
wild type. 
As a conclusion, the creation of a clean “natural product free background strain” 
failed, but the attempt to do so allowed further insights into the complex metabolic 
network used by M. xanthus. The suggested use of Sfp-type PPTases in addition to 
MxAcpS for the activation of fatty acid biosynthesis carrier proteins gives another 
example for the connection of primary and secondary metabolism in this strain, a 
feature that was described before, e.g. for the supply with branched chain carboxylic 
acid precursors for primary and secondary metabolite production (11,14,88). 
One promising alternative towards the attempt to discriminate between secondary 
metabolites and the occurring background noise in the natural producer is given by 
heterologous expression of the respective biosynthetic pathways in phylogenetically 
distant host organisms. This approach, even though laborious, comprises several 
advantages: First, the identification of the metabolite should be easier since the 
mutant strain containing the gene cluster can be compared directly to its progenitor 
strain (wild type). Second, the biosynthetic pathway can be uncoupled from 
(unknown) required signals for biosynthesis by employing strong constitutive or 
inducible promoters that drive transcription of the gene cluster. Thus, gene clusters 
that are for some reason “silent” in the natural producer can be activated and the 
natural product can subsequently be identified and isolated (45). A similar effect 
would be expected from the introduction of strong promoters into the biosynthetic 
gene cluster in the natural producer itself. Third, gene clusters expressed in 
heterologous hosts are often easier to manipulate genetically when compared to the 
original host, as is the case for E. coli and pseudomonads when compared to 
myxobacteria. This opens the door for better manipulation of the biosynthetic 
pathway, e.g. mutations aiming at alteration of binding pocket substrate specificity or 
the repairing of aberrations identified in the sequence of conserved residues that 
might be responsible for non-production. Finally, as the tools and the knowledge for 
heterologous production become more and more sophisticated, the number of 
examples for secondary metabolites that are produced in higher quantities in the 
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heterologous host when compared to the natural producer will steadily increase 
(151,154). Beyond this, further insights into the chemical diversity of the M. xanthus 
secondary metabolome should pave the way for a better understanding of the role 
natural products play for this extraordinary organism. 
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